FDA — authorised 15 December 2008
- Application: NDA022224
- Marketing authorisation holder: ABBVIE
- Local brand name: TRILIPIX
- Indication: CAPSULE, DELAYED RELEASE — ORAL
- Status: approved
🇺🇸 ABT-335 and rosuvastatin calcium in United States
FDA authorised ABT-335 and rosuvastatin calcium on 15 December 2008
Marketing authorisation
Other Cardiovascular approved in United States
Frequently asked questions
Is ABT-335 and rosuvastatin calcium approved in United States?
Yes. FDA authorised it on 15 December 2008.
Who is the marketing authorisation holder for ABT-335 and rosuvastatin calcium in United States?
ABBVIE holds the US marketing authorisation.